[go: up one dir, main page]

WO1994020115A3 - Acide hyaluronique utilise comme traitement contre le cancer - Google Patents

Acide hyaluronique utilise comme traitement contre le cancer Download PDF

Info

Publication number
WO1994020115A3
WO1994020115A3 PCT/US1994/002506 US9402506W WO9420115A3 WO 1994020115 A3 WO1994020115 A3 WO 1994020115A3 US 9402506 W US9402506 W US 9402506W WO 9420115 A3 WO9420115 A3 WO 9420115A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
cancer treatment
acid used
preparations
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/002506
Other languages
English (en)
Other versions
WO1994020115A2 (fr
Inventor
Karen K Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Priority to AU63625/94A priority Critical patent/AU6362594A/en
Publication of WO1994020115A2 publication Critical patent/WO1994020115A2/fr
Publication of WO1994020115A3 publication Critical patent/WO1994020115A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparations à base d'acide hyaluronique, qui soignent le cancer. Lesdites préparations peuvent contenir d'autres ingrédients tels que de l'acide lipotéichoïque et sont injectées de manière parentérale ou directement dans la tumeur. Toutes les préparations peuvent être utilisées de façon répétée sans effets secondaires toxiques.
PCT/US1994/002506 1993-03-10 1994-03-08 Acide hyaluronique utilise comme traitement contre le cancer Ceased WO1994020115A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63625/94A AU6362594A (en) 1993-03-10 1994-03-08 Hyaluronic acid used as a cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2895793A 1993-03-10 1993-03-10
US08/028,957 1993-03-10

Publications (2)

Publication Number Publication Date
WO1994020115A2 WO1994020115A2 (fr) 1994-09-15
WO1994020115A3 true WO1994020115A3 (fr) 1994-11-10

Family

ID=21846439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002506 Ceased WO1994020115A2 (fr) 1993-03-10 1994-03-08 Acide hyaluronique utilise comme traitement contre le cancer

Country Status (2)

Country Link
AU (1) AU6362594A (fr)
WO (1) WO1994020115A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
WO1996023896A1 (fr) * 1995-01-30 1996-08-08 Peter Truog Preparations antitumorales et anticholesterol contenant un acide lipoteichoique tire de streptococcus
JPH09163896A (ja) * 1995-12-13 1997-06-24 Sumitomo Pharmaceut Co Ltd 胸膜炎病態モデル動物
CA2175282A1 (fr) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
NZ520312A (en) * 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
EP1260227A1 (fr) * 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. L'acide lipoteichoique des bacteries lactiques et son utilisation pour moduler des responses immunitaites induites par des bacteries a gram negatif, gram positif
WO2008041514A1 (fr) * 2006-09-22 2008-04-10 Kochi University Sensibilisateur de rayonnement ou sensibilisateur de chimiothérapie anti-cancer
TR201905159T4 (tr) 2013-02-15 2019-05-21 Kortuc Inc İntratümöral lokal enjeksiyonda ve taşıyıcı olarak hidrojel ile hidrojen peroksidin kontrollü salımı için kullanılacak radyasyon/kemoterapi sensitizörü.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135820A2 (fr) * 1983-08-26 1985-04-03 Chugai Seiyaku Kabushiki Kaisha Agent antitumoral
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
EP0208623A2 (fr) * 1985-07-12 1987-01-14 Sanofi Utilisation de poly- et oligosaccharides pour l'obtention de médicaments actifs dans les pathologies du tissu conjonctif
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
WO1989005646A1 (fr) * 1987-12-21 1989-06-29 Bukh Meditec A/S Utilisations de sucres sulfates
JPH01290631A (ja) * 1988-05-18 1989-11-22 Seikagaku Kogyo Co Ltd 血管内皮細胞増殖抑制剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135820A2 (fr) * 1983-08-26 1985-04-03 Chugai Seiyaku Kabushiki Kaisha Agent antitumoral
US4678773A (en) * 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
EP0208623A2 (fr) * 1985-07-12 1987-01-14 Sanofi Utilisation de poly- et oligosaccharides pour l'obtention de médicaments actifs dans les pathologies du tissu conjonctif
WO1989005646A1 (fr) * 1987-12-21 1989-06-29 Bukh Meditec A/S Utilisations de sucres sulfates
JPH01290631A (ja) * 1988-05-18 1989-11-22 Seikagaku Kogyo Co Ltd 血管内皮細胞増殖抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 90-011032 [02] *
PATENT ABSTRACTS OF JAPAN vol. 10, no. 139 (C - 348) *

Also Published As

Publication number Publication date
AU6362594A (en) 1994-09-26
WO1994020115A2 (fr) 1994-09-15

Similar Documents

Publication Publication Date Title
HK63487A (en) Detergent compositions
WO2000053730A3 (fr) TRAITEMENT DU DEFICIT EN α-GALACTOSIDASE
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
WO2002056912A3 (fr) Methode de traitement du cancer
CA2170255A1 (fr) Composition pharmaceutique pour therapie par immunopotentialisation
AU3139097A (en) Methods of preventing skeletal problems in poultry
AU6801694A (en) The treatment of small animals
WO1998008505A8 (fr) Composes pharmaceutiques
WO1997004788A3 (fr) Utilisation de glycosides de calendula dans le traitement du psoriasis
AU4896090A (en) Insecticide treatment and compositions therefor
EP1008344A4 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
CA2120153A1 (fr) Immunotoxines recombinantes
WO1994020115A3 (fr) Acide hyaluronique utilise comme traitement contre le cancer
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO1998032428A3 (fr) Compositions a base de choline et utilisation de la choline pour traiter les chocs endotoxiques
WO1998030585A3 (fr) Utilisation de pea3 en tant que suppresseur de tumeurs
EP0281070A3 (fr) Composé pharmaceutique pour le traitement du cancer
WO1996021468A3 (fr) Interferent chimiquement modifie
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AU4974793A (en) Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide
ZA935086B (en) Skin regenerating cosmetic composition
NZ231320A (en) Aqueous oral preparations of diclofenac

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA